Ketanserin and Naftopidil Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced Contraction of Human Isolated Urinary Bladder Muscle Strips
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to assess the potential involvement of a specific subtype of 5-hydroxytryptamine (5-HT), 5HT2 receptors in neurally-induced contractions of the human detrusor. Methods: Contractile responses to electrical field stimulation (EFS) were examined in human isolated urinary bladder muscle strips. The potentiation of EFS-induced detrusor contraction was examined by adding cumulative concentrations of a 5-HT and 5-HT2 receptor agonist, α-methyl-serotonin (α-Me-5-HT) (1nM–100μM) in the presence or absence of a 5-HT2 antagonist, ketanserin (5-HT2A>5-HT2C) or naftopidil (5-HT2B>5-HT2A) (0.3–3μM). Results: 5-HT and α-Me-5-HT potentiated EFS-induced contraction with a maximal effect (Emax) of 37.6% and 38.6%, respectively, and with pEC50 (negative logarithm of the concentration required for a half-maximal response to an agonist) values of 8.3 and 6.8, respectively. Neither ketanserin nor naftopidil at any concentration produced a rightward displacement of the α-Me-5-HT concentration response curve. Instead, the Emax of α-Me-5-HT increased in the presence of ketanserin at 0.3–1μM and in the presence of naftopidil at 1μM to 51% and 56%, respectively, while the Emax in the presence of vehicle alone was 36%. The highest concentration (3μM) of either drug, however, fully reversed the enhancement. Conclusions: The potentiating effect of α-Me-5-HT on neurally-induced contraction of human urinary bladder muscle strips was not found to be mediated via any 5-HT2 receptor subtypes. The underlying mechanism for the enhancement of the α-Me- 5-HT potentiating effect on detrusor contractility by ketanserin and naftopidil remains unknown; however, our results suggest that these drugs may be useful for treating contractile dysfunction of the detrusor, as manifested in conditions such as underactive bladder.
Abstract
Purpose: The aim of this study was to assess the potential involvement of a specific subtype of 5-hydroxytryptamine (5-HT), 5HT2 receptors in neurally-induced contractions of the human detrusor. Methods: Contractile responses to electrical field stimulation (EFS) were examined in human isolated urinary bladder muscle strips. The potentiation of EFS-induced detrusor contraction was examined by adding cumulative concentrations of a 5-HT and 5-HT2 receptor agonist, α-methyl-serotonin (α-Me-5-HT) (1nM–100μM) in the presence or absence of a 5-HT2 antagonist, ketanserin (5-HT2A>5-HT2C) or naftopidil (5-HT2B>5-HT2A) (0.3–3μM). Results: 5-HT and α-Me-5-HT potentiated EFS-induced contraction with a maximal effect (Emax) of 37.6% and 38.6%, respectively, and with pEC50 (negative logarithm of the concentration required for a half-maximal response to an agonist) values of 8.3 and 6.8, respectively. Neither ketanserin nor naftopidil at any concentration produced a rightward displacement of the α-Me-5-HT concentration response curve. Instead, the Emax of α-Me-5-HT increased in the presence of ketanserin at 0.3–1μM and in the presence of naftopidil at 1μM to 51% and 56%, respectively, while the Emax in the presence of vehicle alone was 36%. The highest concentration (3μM) of either drug, however, fully reversed the enhancement. Conclusions: The potentiating effect of α-Me-5-HT on neurally-induced contraction of human urinary bladder muscle strips was not found to be mediated via any 5-HT2 receptor subtypes. The underlying mechanism for the enhancement of the α-Me- 5-HT potentiating effect on detrusor contractility by ketanserin and naftopidil remains unknown; however, our results suggest that these drugs may be useful for treating contractile dysfunction of the detrusor, as manifested in conditions such as underactive bladder.
참고문헌 (35)
- Hannon J, "Molecular biology of 5-HT receptors", Behav Brain Res, 195, pp.198~213 (2008)
- Alexander SP, "The Concise Guide to PHARMACOLOGY 2015", 16 : G protein-coupled receptors, 2015, pp.172, 5744~5869
- Anderson KE, "Pharmacology of lower urinary tract smooth muscles and penile erectile tissues", Pharmacol Rev, 45, pp.253~308 (1993)
- Ramage AG., "The role of central 5-hydroxytryptamine (5-HT, serotonin)receptors in the control of micturition", Br J Pharmacol, 147(Suppl 2), pp.S120~S131 (2006)
- Klarskov P, "Influence of serotonin on lower urinary tract smooth muscle in vitro", Br J Urol, 58, pp.507~513 (1986)
- Corsi M, "Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder", Br J Pharmacol, 104, pp.719~725 (1991)
- Candura SM, "Neural 5-HT4 receptors in the human isolated detrusor muscle: effects of indole, benzimidazolone and substituted benzamide agonists and antagonists", Br J Pharmacol, 118, pp.1965~1970 (1996)
- acetylcholine release in the human detrusor, "J Pharmacol Exp Ther", 2006, 129~135
- Imamura T, "Expression of 5-hydroxytryptamine receptors in human urinary bladders with benign prostatic hyperplasia", Adv Ther, 32(Suppl 1), pp.29~37 (2015)
- Baxter G, "5-HT2 receptor subtypes:a family re-united?", Trends Pharmacol Sci, 16, pp.105~110 (1995)
- Ismaiel AM, "Ketanserin analogues : the effect of structural modification on 5-HT2 serotonin receptor binding", J Med Chem, 38, pp.1196~1202 (1995)
- Sakai T, "Naftopidil inhibits 5-hydroxytryptamine-induced bladder contraction in rats", Eur J Pharmacol, 700, pp.194~200 (2013)
- Hørby-Petersen J, "The effects of a new serotonin receptor antagonist(ketanserin)on lower urinary tract function in patients with prostatism", J Urol, 133, pp.1094~1098 (1985)
- Gotoh M, "Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia : a randomized controlled trial", BJU Int, 96, pp.581~586 (2005)
- Farthing MJ, "Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction", Postgrad Med J, 70, pp.363~366 (1994)
- Reimann IW, "Pharmacokinetics of ketanserin in man", Eur J Clin Pharmacol, 25, pp.73~76 (1983)
- de Groat WC, "Modulation of voiding and storage reflexes by activation of alpha1-adrenoceptors", Eur Urol, 36(Suppl 1), pp.68~73 (1999)
- Tonini M, "Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle", Br J Pharmacol, 113, pp.1~2 (1994)
- Ismaiel AM, "5-HT1and 5-HT2 binding profiles of the serotonergic agents alpha-methylserotonin and 2-methylserotonin", J Med Chem, 33, pp.755~758 (1990)
- Feldman PD, "Effects of serotonin-1 and serotonin-2 receptor agonists on neuronal activity in the nucleus tractus solitarius", J Auton Nerv Syst, 56, pp.119~124 (1995)
- Hoyer D, "International Union of Pharmacology classification of receptors for 5-hydroxytryptamine(Serotonin)", Pharmacol Rev, 46, pp.157~203 (1994)
- Campos-Bedolla P, "Alpha-methyl-5-HT, a 5-HT2 receptor agonist, stimulates beta2-adrenoceptors in guinea pig airway smooth muscle", Pharmacol Res, 54, pp.468~473 (2006)
- ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes, "Naunyn Schmiedebergs Arch Pharmacol", 1987, 226~230
- Sorbi C, "1,3-Dioxolane-based ligands as rigid analogues of naftopidil: structure-affinity", activity relationships at alpha1 and 5-HT1A receptors, 2009, pp.4, 393~399
- Israilova M, "Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes", Pharmacology, 65, pp.69~73 (2002)
- Sathi ZS, "Different affinities of native alpha1B-adrenoceptors for ketanserin between intact tissue segments and membrane preparations", Eur J Pharmacol, 584, pp.222~228 (2008)
- Takei R, "Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors", Jpn J Pharmacol, 79, pp.447~454 (1999)
- Borbe HO, "5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug", Eur J Pharmacol, 205, pp.105~107 (1991)
- Sarrouilhe D, "Serotonin and cancer:what is the link?", Curr Mol Med, 15, pp.62~77 (2015)
- Siddiqui EJ, "The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation", BJU Int, 97, pp.634~639 (2006)
- Jungwirth N, "Serotonin used as prognostic marker of urological tumors", World J Urol, 26, pp.499~504 (2008)
- Moreau M, "Bacille Calmette-Guérin inoculation induces chronic activation of peripheral and brain indoleamine 2,3-dioxygenase in mice", J Infect Dis, 192, pp.537~544 (2005)
- Moreau M, "Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior", Brain Behav Immun, 22, pp.1087~1095 (2008)
- Maes M, "The new ‘5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.702~721 (2011)
- O’Connor JC, "Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice", Mol Psychiatry, 14, pp.511~522 (2009)